The DOI matches its Crossref record; 36 of the 36 references it cites were found in a registry or an index.
Cabotegravir for HIV Prevention in Cisgender Men and Transgender Women
Open accessAbstract
BACKGROUND: Safe and effective long-acting injectable agents for preexposure prophylaxis (PrEP) for human immunodeficiency virus (HIV) infection are needed to increase the options for preventing HIV infection. METHODS: We conducted a randomized, double-blind, double-dummy, noninferiority trial to compare long-acting injectable cabotegravir (CAB-LA, an integrase strand-transfer inhibitor [INSTI]) at a dose of 600 mg, given intramuscularly every 8 weeks, with daily oral tenofovir disoproxil fumarate-emtricitabine (TDF-FTC) for the prevention of HIV infection in at-risk cisgender men who have sex with men (MSM) and in at-risk transgender women who have sex with men. Participants were randomly assigned (1:1) to receive one of the two regimens and were followed for 153 weeks. HIV testing and safety evaluations were performed. The primary end point was incident HIV infection. RESULTS: The intention-to-treat population included 4566 participants who underwent randomization; 570 (12.5%) identified as transgender women, and the median age was 26 years (interquartile range, 22 to 32). The trial was stopped early for efficacy on review of the results of the first preplanned interim end-point analysis. Among 1698 participants from the United States, 845 (49.8%) identified as Black. Incident HIV infection occurred in 52 participants: 13 in the cabotegravir group (incidence, 0.41 per 100 person-years) and 39 in the TDF-FTC group (incidence, 1.22 per 100 person-years) (hazard ratio, 0.34; 95% confidence interval, 0.18 to 0.62). The effect was consistent across prespecified subgroups. Injection-site reactions were reported in 81.4% of the participants in the cabotegravir group and in 31.3% of those in the TDF-FTC group. In the participants in whom HIV infection was diagnosed after exposure to CAB-LA, INSTI resistance and delays in the detection of HIV infection were noted. No safety concerns were identified. CONCLUSIONS: CAB-LA was superior to daily oral TDF-FTC in preventing HIV infection among MSM and transgender women. Strategies are needed to prevent INSTI resistance in cases of CAB-LA PrEP failure. (Funded by the National Institute of Allergy and Infectious Diseases and others; HPTN 083 ClinicalTrials.gov number, NCT02720094.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Prediction of Creatinine Clearance from Serum Creatinine
Cockcroft, D. W., & Gault, H. (1976) · Nephron · doi:10.1159/000180580 · Cited by 15,309
Preexposure chemoprophylaxis for HIV prevention in men who have sex with men.
Grant, R. M., Lama, J. R., Anderson, P. L., McMahan, V., Liu, A. Y., Vargas, L., Goicochea, P., Casapía, M., Guanira-Carranza, J. V., Ramirez-Cardich, M. E., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1011205 · Cited by 5,096
Self-citationAntiretroviral prophylaxis for HIV prevention in heterosexual men and women.
Baeten, J. M., Donnell, D., Ndase, P., Mugo, N. R., Campbell, J. D., Wangisi, J., Tappero, J. W., Bukusi, E. A., Cohen, C. R., Katabira, E., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1108524 · Cited by 3,256
Self-citationAntiretroviral preexposure prophylaxis for heterosexual HIV transmission in Botswana.
Thigpen, M. C., Kebaabetswe, P. M., Paxton, L. A., Smith, D. K., Rose, C. E., Segolodi, T. M., Henderson, F. L., Pathak, S. R., Soud, F. A., Chillag, K. L., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1110711 · Cited by 1,996
Self-citationOn-Demand Preexposure Prophylaxis in Men at High Risk for HIV-1 Infection
Molina, J.-M., Capitant, C., Spire, B., Pialoux, G., Cotte, L., Charreau, I., Tremblay, C., Le Gall, J.-M., Cua, E., Pasquet, A., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1506273 · Cited by 1,633
Self-citationChoopanya, K., Martin, M., Suntharasamai, P., Sangkum, U., Mock, P. A., Leethochawalit, M., Chiamwongpaet, S., Kitisin, P., Natrujirote, P., Kittimunkong, S., et al. (2013) · The Lancet · doi:10.1016/s0140-6736(13)61127-7 · Cited by 1,463
Self-citationTenofovir-based preexposure prophylaxis for HIV infection among African women.
Marrazzo, J. M., Ramjee, G., Richardson, B. A., Gomez, K., Mgodi, N., Nair, G., Palanee, T., Nakabiito, C., van der Straten, A., Noguchi, L., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1402269 · Cited by 1,296
Grant, R. M., Anderson, P. L., McMahan, V., Liu, A., Amico, K. R., Mehrotra, M., Hosek, S., Mosquera, C., Casapia, M., Montoya, O., et al. (2014) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(14)70847-3 · Cited by 1,208
Self-citationSax, P. E., Erlandson, K. M., Lake, J. E., Mccomsey, G. A., Orkin, C., Esser, S., Brown, T. T., Rockstroh, J. K., Wei, X., Carter, C. C., et al. (2020) · Clinical Infectious Diseases · doi:10.1093/cid/ciz999 · Cited by 768
Self-citationDolutegravir plus two different prodrugs of tenofovir to treat HIV
Venter, W. D. F., Moorhouse, M., Sokhela, S., Fairlie, L., Mashabane, N., Masenya, M., Serenata, C., Akpomiemie, G., Qavi, A., Chandiwana, N., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1902824 · Cited by 723
Müller, R. H., Gohla, S., & Keck, C. M. (2011) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2011.01.007 · Cited by 702
Long-Acting Cabotegravir and Rilpivirine for Maintenance of HIV-1 Suppression
Swindells, S., Andrade-Villanueva, J.-F., Richmond, G. J., Rizzardini, G., Baumgarten, A., Masiá, M., Latiff, G., Pokrovsky, V., Bredeek, F., Smith, G., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa1904398 · Cited by 594
Self-citationMargolis, D. A., Gonzalez-Garcia, J., Stellbrink, H.-J., Eron, J. J., Yazdanpanah, Y., Podzamczer, D., Lutz, T., Angel, J. B., Richmond, G. J., Clotet, B., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)31917-7 · Cited by 499
Self-citationLong-Acting Cabotegravir and Rilpivirine after Oral Induction for HIV-1 Infection
Orkin, C., Arasteh, K., Górgolas Hernández-Mora, M., Pokrovsky, V., Overton, E. T., Girard, P.-M., Oka, S., Walmsley, S., Bettacchi, C., Brinson, C., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa1909512 · Cited by 487
Self-citationMayer, K. H., Molina, J.-M., Thompson, M. A., Anderson, P. L., Mounzer, K. C., De Wet, J. J., DeJesus, E., Jessen, H., Grant, R. M., Ruane, P. J., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)31065-5 · Cited by 428
Self-citationProblem-Solving Therapy: A Positive Approach to Clinical Intervention
D’Zurilla, T. J., & Nezu, A. M. (2006) · Cited by 424
Greater Weight Gain in Treatment-naive Persons Starting Dolutegravir-based Antiretroviral Therapy
Bourgi, K., Rebeiro, P. F., Turner, M., Castilho, J. L., Hulgan, T., Raffanti, S. P., Koethe, J. R., & Sterling, T. R. (2020) · Clinical Infectious Diseases · doi:10.1093/cid/ciz407 · Cited by 327
Castillo-Mancilla, J. R., Zheng, J.-H., Rower, J. E., Meditz, A., Gardner, E. M., Predhomme, J., Fernandez, C., Langness, J., Kiser, J. J., Bushman, L. R., et al. (2013) · AIDS Research and Human Retroviruses · doi:10.1089/aid.2012.0089 · Cited by 315
Self-citationParameter estimation following group sequential hypothesis testing
EMERSON, S. S., & FLEMING, T. R. (1990) · Biometrika · doi:10.1093/biomet/77.4.875 · Cited by 224
Markowitz, M., Frank, I., Grant, R. M., Mayer, K. H., Elion, R., Goldstein, D., Fisher, C., Sobieszczyk, M. E., Gallant, J. E., Van Tieu, H., et al. (2017) · The Lancet HIV · doi:10.1016/s2352-3018(17)30068-1 · Cited by 214
Self-citationLandovitz, R. J., Li, S., Eron, J. J., Grinsztejn, B., Dawood, H., Liu, A. Y., Magnus, M., Hosseinipour, M. C., Panchia, R., Cottle, L., et al. (2020) · The Lancet HIV · doi:10.1016/s2352-3018(20)30106-5 · Cited by 183
Self-citationLife-steps: Applying cognitive behavioral therapy to HIV medication adherence
Safren, S. A., Otto, M. W., & Worth, J. L. (1999) · Cognitive and Behavioral Practice · doi:10.1016/s1077-7229(99)80052-2 · Cited by 179
Self-citationLandovitz, R. J., Li, S., Grinsztejn, B., Dawood, H., Liu, A. Y., Magnus, M., Hosseinipour, M. C., Panchia, R., Cottle, L., Chau, G., et al. (2018) · PLOS Medicine · doi:10.1371/journal.pmed.1002690 · Cited by 172
Self-citationAndrews, C. D., Spreen, W. R., Mohri, H., Moss, L., Ford, S., Gettie, A., Russell-Lodrigue, K., Bohm, R. P., Cheng-Mayer, C., Hong, Z., et al. (2014) · Science · doi:10.1126/science.1248707 · Cited by 164
Self-citationSolomon, M. M., Mayer, K. H., Glidden, D. V., Liu, A. Y., McMahan, V. M., Guanira, J. V., Chariyalertsak, S., Fernandez, T., Grant, R. M., Bekker, L.-G., et al. (2014) · Clinical Infectious Diseases · doi:10.1093/cid/ciu450 · Cited by 159
Self-citationMurnane, P. M., Celum, C., Mugo, N., Campbell, J. D., Donnell, D. J., Bukusi, E. A., Mujugira, A., Tappero, J. W., Kahle, E., Thomas, K. K., et al. (2013) · AIDS · doi:10.1097/qad.0b013e3283629037 · Cited by 158
Self-citationSpreen, W. R., Ford, S. L., Chen, S., Wilfret, D. A., Margolis, D. M., Gould, E. P., & Piscitelli, S. C. (2014) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/qai.0000000000000301 · Cited by 146
Self-citationMarzinke, M. A., Grinsztejn, B. G. J., Fogel, J. M., Piwowar‐Manning, E., Li, M., Weng, L., McCauley, M., Cummings, V., Ahmed, S., Haines, C. D., et al. (2021) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiab152 · Cited by 136
Self-citationBarbee, L. A., Khosropour, C. M., Dombrowksi, J. C., & Golden, M. R. (2017) · Sexually Transmitted Diseases · doi:10.1097/olq.0000000000000614 · Cited by 92
Hoornenborg, E., Prins, M., Achterbergh, R., Woittiez, L. R., Cornelissen, M. T. E., Jurriaans, S., Kootstra, N. A., Anderson, P. L., Reiss, P., de Vries, H. J. C., et al. (2017) · The Lancet HIV · doi:10.1016/s2352-3018(17)30132-7 · Cited by 81
Self-citationCabotegravir long acting injection protects macaques against intravenous challenge with SIVmac251
Andrews, C. D., Bernard, L. S., Poon, A. Y., Mohri, H., Gettie, N., Spreen, W. R., Gettie, A., Russell‐Lodrigue, K., Blanchard, J., Hong, Z., et al. (2016) · AIDS · doi:10.1097/qad.0000000000001343 · Cited by 44
Self-citationRadzio‐Basu, J., Cong, M., Ruone, S. J., Newton, A., Wei, X., Mitchell, J. M., Ellis, S., Petropoulos, C. J., Huang, W., Spreen, W. R., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-10047-w · Cited by 35
Self-citationMullick, C., & Murray, J. S. (2019) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiz037 · Cited by 33
Dobard, C., Makarova, N., Nishiura, K., Dinh, C. T., Holder, A. N., Sterling, M., Lipscomb, J. T., Mitchell, J. M., Deyounks, F., Garber, D. A., et al. (2020) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiaa095 · Cited by 21
Self-citationBiello, K. B., Psaros, C., Krakower, D., Marrow, E., Safren, S. A., Mimiaga, M. J., Hightow‐Weidman, L., Sullivan, P. S., & Mayer, K. H. (2018) · JMIR Research Protocols · doi:10.2196/10661 · Cited by 18
Self-citationA Nonhuman Primate Model for Rectally Transmitted Syphilis
Tansey, C., Zhao, C., Hopkins, A., Ritter, J. M., Fakile, Y. F., Pillay, A., Katz, S. S., Pereira, L., Mitchell, J. M., Deyounks, F., et al. (2017) · The Journal of Infectious Diseases · doi:10.1093/infdis/jix669 · Cited by 7
Cited by
Delany-Moretlwe, S., Hughes, J. P., Bock, P., Ouma, S. G., Hunidzarira, P., Kalonji, D., Kayange, N., Makhema, J., Mandima, P., Mathew, C., et al. (2022) · The Lancet · doi:10.1016/s0140-6736(22)00538-4 · Cited by 586
Self-citationGandhi, R. T., Bedimo, R., Hoy, J. F., Landovitz, R. J., Smith, D. M., Eaton, E. F., Lehmann, C., Springer, S. A., Sax, P. E., Thompson, M. A., et al. (2023) · JAMA · doi:10.1001/jama.2022.22246 · Cited by 557
Self-citationTwice-Yearly Lenacapavir or Daily F/TAF for HIV Prevention in Cisgender Women
Bekker, L.-G., Das, M., Abdool Karim, Q., Ahmed, K., Batting, J., Brumskine, W., Gill, K., Harkoo, I., Jaggernath, M., Kigozi, G., et al. (2024) · New England Journal of Medicine · doi:10.1056/nejmoa2407001 · Cited by 523
Overcoming barriers to patient adherence: the case for developing innovative drug delivery systems
Baryakova, T. H., Pogostin, B. H., Langer, R., & McHugh, K. J. (2023) · Nature Reviews Drug Discovery · doi:10.1038/s41573-023-00670-0 · Cited by 492
Twice-Yearly Lenacapavir for HIV Prevention in Men and Gender-Diverse Persons
Kelley, C. F., Acevedo-Quiñones, M., Agwu, A. L., Avihingsanon, A., Benson, P., Blumenthal, J., Brinson, C., Brites, C., Cahn, P., Cantos, V. D., et al. (2025) · New England Journal of Medicine · doi:10.1056/nejmoa2411858 · Cited by 296
Self-citation
Metadata
- Authors
- Landovitz, R. J., Donnell, D., Clement, M. E., Hanscom, B., Cottle, L., Coelho, L., Cabello, R., Chariyalertsak, S., Dunne, E. F., Frank, I., Gallardo-Cartagena, J. A., Gaur, A. H., Gonzales, P., Tran, H. V., Hinojosa, J. C., Kallas, E. G., Kelley, C. F., Losso, M. H., Madruga, J. V., Middelkoop, K., Phanuphak, N., Santos, B., Sued, O., Valencia Huamaní, J., Overton, E. T., Swaminathan, S., del Rio, C., Gulick, R. M., Richardson, P., Sullivan, P., Piwowar-Manning, E., Marzinke, M., Hendrix, C., Li, M., Wang, Z., Marrazzo, J., Daar, E., Asmelash, A., Brown, T. T., Anderson, P., Eshleman, S. H., Bryan, M., Blanchette, C., Lucas, J., Psaros, C., Safren, S., Sugarman, J., Scott, H., Eron, J. J., Fields, S. D., Sista, N. D., Gomez-Feliciano, K., Jennings, A., Kofron, R. M., Holtz, T. H., Shin, K., Rooney, J. F., Smith, K. Y., Spreen, W., Margolis, D., Rinehart, A., Adeyeye, A., Cohen, M. S., McCauley, M., & Grinsztejn, B.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2021-08-12
- Volume
- 385
- Issue
- 7
- Pages
- 595-608
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W3190424399
- Cited by
- 900
- References
- 36
- FWCI
- 39.16
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.